Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
European Journal of Clinical Pharmacology · 2026-04 · 82 (4)
DOI: 10.1007/s00228-026-04023-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 11.03.2026. Verfasst von Lorenzo Falsetti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy. l.falsetti@staff.univpm.it. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Politecnica delle Marche.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Sodium-glucose transporter 2 inhibitors (SGLT2i) are widely used for diabetes management and have demonstrated benefits in treating acute and chronic heart failure (HF) and chronic kidney disease (CKD). Their increasing application has revealed various side effects, although only a few are currently recognized as drug-related adverse events, based on ongoing observations.
Aims
This review synthesizes positive and negative side effects linked to SGLT2i and proposes management strategies.
Methods
A literature search of PubMed/EMBASE, Web of Science, and Google Scholar from the past 10 years identified randomized trials, meta-analyses, observational cohorts, and pharmacovigilance studies reporting SGLT2i-related events across genitourinary, endocrine, metabolic, hematologic, skeletal, and vascular domains.
Results
Data indicate an increased incidence of genital infections (GIs) in diabetic subjects, while associations with urinary tract infections (UTIs) are less consistent. Non-diabetic HF/CKD patients show modest increases in GIs and UTIs. SGLT2i modestly increase hematocrit and may reveal clonal erythrocytosis. Rare conditions like Fournier’s gangrene have been reported, though without a clearly increased risk in clinical trials: all the reported cases led to drug discontinuation. There is no conclusive evidence linking SGLT2i to fractures or osteoporosis, and risk of lower-limb amputation appears comparable to DPP-4 inhibitors, with some trend compared to GLP-1 receptor agonists, suggesting caution in patients with peripheral artery disease. Observational data suggest SGLT2i may protect against syncope and reduce acute kidney injury.
Conclusions
Overall, SGLT2i are safe, with manageable adverse events such as GIs and UTIs. A thorough understanding of potential complications is essential for clinicians to optimize patients’ management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy. l.falsetti@staff.univpm.it.
- Dipartimento Percorsi Medici, U.O.C. Medicina Interna, INRCA-IRCCS, Presidio Ospedaliero di Osimo, Ancona, Italy.
- UOC Medicina Interna, Ospedale Santa Maria della Misericordia Urbino, Azienda Sanitaria Locale 1, Pesaro-Urbino, Italy.
- Scuola di Specializzazione in Medicina d'Emergenza-Urgenza, Università Politecnica delle Marche, Ancona, Italy.
- Pronto Soccorso, Dipartimento di Emergenza-Urgenza, Azienda Ospedaliero-Universitaria Delle Marche, Ancona, Italy.
- Dipartimento di Emergenza-Urgenza, Medicina Interna Generale e Subintensiva, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
Förderung
- Università Politecnica delle Marche
Zitieren
APA
Falsetti, L., Tarquinio, N., Mucci, L., Santini, S., Guerrieri, E., Giovenali, L., Pierdomenico, G., Zaccone, V., Viticchi, G., & Moroncini, G. (2026). Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors. European Journal of Clinical Pharmacology, 82(4). https://doi.org/10.1007/s00228-026-04023-9
Vancouver
Falsetti L, Tarquinio N, Mucci L, Santini S, Guerrieri E, Giovenali L, et al. Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors. European Journal of Clinical Pharmacology. 2026;82(4). doi:10.1007/s00228-026-04023-9
BibTeX
@article{Falsetti2026,
author = {Falsetti, Lorenzo and Tarquinio, Nicola and Mucci, Luciano and Santini, Silvia and Guerrieri, Emanuele and Giovenali, Laura and Pierdomenico, Giulia and Zaccone, Vincenzo and Viticchi, Giovanna and Moroncini, Gianluca},
title = {Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {4},
doi = {10.1007/s00228-026-04023-9}
}
EUVIMED